| 2.56 0.09 (3.64%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.45 |
1-year : | 4.03 |
| Resists | First : | 2.96 |
Second : | 3.45 |
| Pivot price | 2.28 |
|||
| Supports | First : | 2.39 |
Second : | 2.04 |
| MAs | MA(5) : | 2.36 |
MA(20) : | 2.33 |
| MA(100) : | 1.92 |
MA(250) : | 1.59 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.2 |
D(3) : | 63.1 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 2.96 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CERS ] has closed Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.58 | 2.58 - 2.59 |
| Low: | 2.35 - 2.36 | 2.36 - 2.37 |
| Close: | 2.54 - 2.56 | 2.56 - 2.57 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Tue, 17 Feb 2026
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - marketscreener.com
Tue, 17 Feb 2026
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Business Wire
Thu, 12 Feb 2026
Cerus (CERS) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Tue, 27 Jan 2026
Cerus (NASDAQ:CERS) Shares Pass Above 200 Day Moving Average - Here's What Happened - MarketBeat
Fri, 23 Jan 2026
Cerus Corporation (NASDAQ:CERS) Held Back By Insufficient Growth Even After Shares Climb 27% - simplywall.st
Mon, 12 Jan 2026
Cerus expects 14% jump in 2025 topline, guides 2026 (CERS:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 192 (M) |
| Shares Float | 177 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 7,140 (K) |
| Shares Short P.Month | 6,240 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -8.1 % |
| Operating Margin | 2.3 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | 14.5 % |
| Gross Profit (p.s.) | 0.57 |
| Sales Per Share | 1.03 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -32 |
| PEG Ratio | 0 |
| Price to Book value | 8 |
| Price to Sales | 2.46 |
| Price to Cash Flow | 137.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|